ALG.APV-527

Multispecific antibody

Phase 1/24-1BB (CD137) x 5T4No recent registered activity
Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Solid Tumors

Competitive landscape

This drug's own stage for Solid Tumors: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
ALG.APV-527: this drugPhase 1/2Multispecific antibody4-1BB (CD137) x 5T4not yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)Weak signalNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETnot yet gradedNo reviewed efficacy summary in this indication
CR-001
Phase 1/2(overall)
Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
EB-SELECT Dual-Target CAR-NK CellsPhase 1/2Cell therapyTumor antigen menu (TROP2, MSLN, B7-H3, HER2)not yet gradedNo reviewed efficacy summary in this indication
EB-SELECT Single-Target CAR-NK CellsPhase 1/2Cell therapyPersonalized, biomarker-guided allogeneic chimeric antigen receptornot yet gradedNo reviewed efficacy summary in this indication
Micvotabart PelidotinPhase 1/2Antibody–drug conjugateED-B domain of fibronectinnot yet gradedNo reviewed efficacy summary in this indication
Linebacker
—(overall)
Small moleculePIM kinases (PIM1/2/3)not yet gradedNo reviewed efficacy summary in this indication
RP3DiscontinuedOncolytic virusTumor cells (oncolytic replication)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.